FDA accepts New Drug Application (NDA) and Priority Review for ripretinib for treatment of advanced gastrointestinal stromal tumours (GIST)

NDA submission for this broad-spectrum KIT and PDGFRα inhibitor is supported by positive results from INVICTUS phase 3 study in 129 patients whose previous therapies have included at least imatinib, sunitinib, and regorafenib, which achieved primary endpoint of improved PFS.


Biospace Inc.